Welcome to AstraZeneca United States
Beginning its journey in 1953, AstraZeneca became one of the first pharmaceutical companies operating in the United States
Latest News from AstraZeneca United States
US FDA approves TAGRISSO® (osimertinib) as 1st-line treatment for EGFR-mutated non-small cell lung cancer
1st-line use of TAGRISSO offers a potential new standard of care
TAGRISSO delivered unprecedented median progression-free survival of 18.9 months versus 10.2 months for EGFR-TKIs (erlotinib or gefitinib) in 1st-line EGFRm NSCLC
Updated overall survival data for LYNPARZA® (olaparib) in gBRCA-mutated HER2-negative metastatic breast cancer presented at AACR
AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today presented data from the Phase III OlympiAD trial, showing the final overall survival (OS) results for LYNPARZA® (olaparib) in metastatic breast cancer at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, April 14-18, 2018.
Latest AZ&You Blog Articles
If you are passionate about science, these stories will show you how the latest and most exciting projects we have been working on and the people behind them.